DNDi
New hepatitis C combo boasts 97% cure rate for just $300
April 12, 2018Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
